SharpyGLP-1 for Prediabetes: New AHA Study vs Metformin (2026)
GLP-1 medicines are not FDA approved for prediabetes on their own, but a new study released by the American Heart Association on November 2, 2026 found that adults with prediabetes and obesity who took a GLP-1 had a 31% lower risk of type 2 diabetes and were 1.5 times more likely to get back to normal blood sugar than similar adults on metformin. It is an observational records study, so it shows a link, not proof. If you do start a GLP-1, Sharpy helps you keep the muscle that helps control blood sugar, with one protein target and one 20-minute workout a day.
Can a GLP-1 medicine help with prediabetes, and does it beat metformin? A large new study says GLP-1 users did better. Researchers from the Mayo Clinic looked at records of 256,492 adults with prediabetes and obesity. Compared with people who took metformin, people who took a GLP-1 had a 31% lower risk of type 2 diabetes and a 1.5 times higher chance of getting back to normal blood sugar. The American Heart Association released the findings on November 2, 2026, ahead of its Scientific Sessions in Chicago (November 6 to 9). But no GLP-1 is approved for prediabetes alone, and this study cannot prove the drug caused the difference. Here is what it found and what it means for you.
What the new AHA prediabetes study found
The study used the TriNetX health records network, which covers 104 institutions, with data from 2010 to 2023. The average patient was 52, and 76% were women. About half took a GLP-1 (semaglutide, tirzepatide, liraglutide or dulaglutide) and half took metformin. The two groups were matched for age, health conditions such as high blood pressure and sleep apnea, and other medicines. People were followed for about 3 years on average.
| Outcome, GLP-1 users vs metformin users | Result |
|---|---|
| Return to normal blood sugar | 1.5 times more likely |
| New type 2 diabetes | 31% lower risk |
| Death from any cause | 41% lower risk |
| Heart attacks | 15% fewer |
| Strokes | 20% fewer |
| Heart failure | 25% fewer |
| Atrial fibrillation | 8% fewer |
The release did not give the exact percentages of people in each group, and the abstract has not yet been published as a full paper. The study author is Vinicius de Sousa Barzon Serra, M.D., a research fellow in cardiovascular medicine at Mayo Clinic in Scottsdale, Arizona.
What the study cannot tell you
The AHA was clear about the limits. Read these before you take the numbers to your doctor:
- It is observational. People were not randomly assigned to a drug. Doctors may have picked GLP-1s for people who were different in ways the records did not capture.
- Diagnosis codes can be incomplete. Some outcomes may be missed.
- Prescriptions are not proof of use. The records do not show how often people actually took the medicine or at what dose.
- The drugs were lumped together. It does not say whether semaglutide, tirzepatide, liraglutide or dulaglutide did best.
So the right reading is: GLP-1 users with prediabetes and obesity did better than metformin users in real-world records. It is a strong signal, not a final answer.
Is a GLP-1 approved for prediabetes?
No. As of November 2026, no GLP-1 has an FDA approval for prediabetes by itself. Metformin is not FDA approved for prediabetes either, but it has decades of trial data behind it and is the usual first medicine doctors consider, along with lifestyle changes.
People with prediabetes usually get a GLP-1 through a different door: the weight-management indication. Wegovy (semaglutide) and Zepbound (tirzepatide) are approved for adults with obesity, or with overweight plus at least one weight-related health condition. Ozempic and Mounjaro are approved for type 2 diabetes, which prediabetes is not. Our GLP-1 medication comparison lays out every brand and its approved uses.
How GLP-1s compare with metformin and lifestyle in prediabetes
The new study is the first big look at GLP-1 versus metformin in prediabetes. The older trials each compared one option with placebo, so they are not head to head. Still, they show the size of each effect:
| Study | What was tested | Result |
|---|---|---|
| Diabetes Prevention Program (NEJM, 2002), 3,234 adults, 2.8 years | Lifestyle program vs placebo | 58% lower risk of type 2 diabetes |
| Diabetes Prevention Program (NEJM, 2002) | Metformin 850 mg twice daily vs placebo | 31% lower risk of type 2 diabetes |
| STEP 1 prediabetes analysis (Diabetes Care, 2022) | Semaglutide 2.4 mg vs placebo, 68 weeks | 84.1% vs 47.8% had normal blood sugar |
| STEP 10 (Lancet Diabetes Endocrinol, 2024) | Semaglutide 2.4 mg vs placebo, 52 weeks | 81% vs 14% had normal blood sugar |
| AHA 2026 records study, about 3 years | GLP-1 vs metformin | 31% lower risk of type 2 diabetes with GLP-1 |
Two things stand out. First, lifestyle change was the strongest single tool in the classic trial, and in the GLP-1 trials both groups got lifestyle advice too. Second, GLP-1 trials measured a big swing back to normal blood sugar, mostly driven by weight loss.
Who might be a candidate for a GLP-1 with prediabetes
This is a decision for you and your prescriber. Things they usually look at:
- Your weight and BMI, because that decides whether the weight-management label applies.
- Other conditions, such as high blood pressure, sleep apnea, high cholesterol, fatty liver or heart disease.
- Your A1C. Prediabetes is an A1C of 5.7% to 6.4%, or a fasting glucose of 100 to 125 mg/dL.
- What you have already tried, including a structured lifestyle program.
- Safety, including any history of pancreatitis, or a personal or family history of medullary thyroid cancer or MEN 2, which are on the label warnings.
If you are pregnant, planning a pregnancy, under 18 or have a history of an eating disorder, talk to your doctor before any of these medicines. Our GLP-1 and insulin resistance guide explains how these drugs act on blood sugar in the first place.
Will insurance cover a GLP-1 for prediabetes?
Usually not for prediabetes alone. Coverage normally depends on whether your plan covers weight-management drugs at all, and whether you meet its rules, which often include a BMI cutoff and prior authorization. Some large employers have dropped GLP-1 weight-loss coverage this year. If you are 65 or older, see our Medicare GLP-1 Bridge guide. If you are paying cash, our Wegovy pill cost guide covers current self-pay prices.
Why muscle matters when you have prediabetes
Muscle is the biggest place your body stores blood sugar after a meal. That makes it one of your best tools against prediabetes. GLP-1 medicines cause fast weight loss, and in trials part of that loss was lean mass. Losing muscle works against the very thing you are trying to fix.
Three habits help:
- Eat protein at every meal. Aim for a palm-sized portion even when your appetite is small. Our protein target guide shows how to set a daily number.
- Lift something twice a week. Short strength sessions are enough to signal your body to keep muscle.
- Walk after meals. A 10-minute walk after eating helps your muscles pull sugar out of the blood.
Sharpy puts all three into one daily plan: a protein target sized to you, one 20-minute workout and a Shape Score that shows whether you are losing fat or muscle.
The bottom line
The November 2026 AHA study is good news for people with prediabetes and obesity. GLP-1 users had less diabetes, fewer heart events and lower death rates than metformin users in real-world records. But it is not a trial, GLP-1s are not approved for prediabetes alone, and lifestyle change still has the strongest evidence. Bring the study to your doctor, ask whether a weight-management GLP-1 fits you, and keep building muscle either way. Sharpy makes that daily part simple.
Sources
- American Heart Association: GLP-1 meds linked to lower diabetes, heart risks than standard diabetes prevention med (Nov 2, 2026)
- AJMC: GLP-1 Use Tied to Lower Diabetes, CV Risk vs Metformin in Prediabetes (Nov 2, 2026)
- Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. NEJM 2002
- Perreault L et al. Glycemic status with semaglutide 2.4 mg among participants with prediabetes in the STEP program. Diabetes Care 2022
- McGowan BM et al. STEP 10. Lancet Diabetes Endocrinol 2024
- Wegovy (semaglutide) prescribing information (openFDA)
- Zepbound (tirzepatide) prescribing information (openFDA)
Questions people ask
Is there a GLP-1 approved for prediabetes?
No. As of November 2026, no GLP-1 medicine has an FDA indication for prediabetes by itself. Wegovy and Zepbound are approved for weight management in adults with obesity, or with overweight plus at least one weight-related condition. Some people with prediabetes qualify that way. Whether you qualify is your prescriber's call.
Is a GLP-1 better than metformin for prediabetes?
A Mayo Clinic study presented at AHA Scientific Sessions 2026 linked GLP-1 use to a 31% lower risk of type 2 diabetes and a 41% lower risk of death than metformin. But it compared patient records, not randomized groups, and it has not been published as a full paper yet. A head-to-head trial has not been done.
Can a GLP-1 reverse prediabetes?
In trials, many people did return to normal blood sugar. In STEP 1, 84.1% of people with prediabetes on semaglutide 2.4 mg had normal blood sugar at week 68, versus 47.8% on placebo. In STEP 10, the figures were 81% versus 14% at 52 weeks. Lifestyle changes were part of both groups.
Will insurance cover a GLP-1 for prediabetes?
Usually not for prediabetes alone, because it is not an approved use. Coverage normally depends on the weight-management indication and your plan's rules. Many plans require prior authorization, and some employers have dropped weight-loss coverage. Call your plan and ask about Wegovy or Zepbound for weight management.
Does Medicare cover GLP-1s for prediabetes?
Not for prediabetes itself. Medicare drug plans can cover Wegovy for heart risk reduction or Zepbound for sleep apnea when those labels apply, and the separate Medicare GLP-1 Bridge program covers some weight-loss use. Check our Medicare GLP-1 Bridge guide for the details.
Which GLP-1 was used in the new prediabetes study?
The study grouped semaglutide, tirzepatide, liraglutide and dulaglutide together and did not compare them with each other. So it cannot tell you which one is best for prediabetes.